Roth Mkm Begins Coverage on Entrada Therapeutics (NASDAQ:TRDA)

Investment analysts at Roth Mkm started coverage on shares of Entrada Therapeutics (NASDAQ:TRDA - Get Free Report) in a research report issued on Thursday, Marketbeat Ratings reports. The firm set a "buy" rating and a $29.00 price target on the stock. Roth Mkm's price objective points to a potential upside of 34.32% from the stock's previous close.

TRDA has been the topic of several other reports. HC Wainwright lifted their target price on shares of Entrada Therapeutics from $18.00 to $20.00 and gave the stock a "buy" rating in a research report on Wednesday, November 6th. Oppenheimer lifted their price objective on shares of Entrada Therapeutics from $25.00 to $28.00 and gave the stock an "outperform" rating in a research report on Wednesday, November 6th.

Entrada Therapeutics Stock Performance

TRDA traded up $1.27 during trading on Thursday, reaching $21.59. The company had a trading volume of 81,524 shares, compared to its average volume of 135,822. The firm's 50-day simple moving average is $18.09 and its 200 day simple moving average is $16.47. The company has a market cap of $807.90 million, a price-to-earnings ratio of 13.58 and a beta of -0.18. Entrada Therapeutics has a 12-month low of $11.35 and a 12-month high of $21.63.

Insider Buying and Selling at Entrada Therapeutics

In related news, CFO Kory James Wentworth sold 3,195 shares of Entrada Therapeutics stock in a transaction on Monday, September 9th. The stock was sold at an average price of $14.97, for a total transaction of $47,829.15. Following the completion of the sale, the chief financial officer now owns 76,486 shares of the company's stock, valued at approximately $1,144,995.42. This trade represents a 4.01 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Natarajan Sethuraman sold 2,700 shares of the company's stock in a transaction dated Wednesday, November 13th. The stock was sold at an average price of $20.04, for a total value of $54,108.00. Following the completion of the transaction, the insider now directly owns 160,888 shares in the company, valued at approximately $3,224,195.52. The trade was a 1.65 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 27,934 shares of company stock valued at $515,582 in the last 90 days. 7.59% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Entrada Therapeutics

Several large investors have recently made changes to their positions in TRDA. US Bancorp DE bought a new stake in Entrada Therapeutics in the third quarter worth $42,000. SG Americas Securities LLC bought a new stake in shares of Entrada Therapeutics during the 3rd quarter worth about $156,000. Acadian Asset Management LLC increased its holdings in shares of Entrada Therapeutics by 135.1% during the 2nd quarter. Acadian Asset Management LLC now owns 13,367 shares of the company's stock valued at $190,000 after acquiring an additional 7,682 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in shares of Entrada Therapeutics by 34.7% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 14,156 shares of the company's stock valued at $226,000 after acquiring an additional 3,644 shares in the last quarter. Finally, Public Employees Retirement System of Ohio lifted its holdings in Entrada Therapeutics by 89.1% in the 3rd quarter. Public Employees Retirement System of Ohio now owns 16,259 shares of the company's stock worth $260,000 after purchasing an additional 7,659 shares during the last quarter. Institutional investors own 86.39% of the company's stock.

Entrada Therapeutics Company Profile

Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.